Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
38.82%
Operating Margin
26.92%
Net Margin
14.63%
Efficiency Metrics
Revenue per Expense Ratio
1.37
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
79.21%
Income Tax Rate
0.00%
EPS
0.2300000000
Balance Sheet Analysis
Current Ratio
0.02
Cash Ratio
0.01
Working Capital
$-604.99M
Debt to Equity
1.07
Debt to Assets
49.24%
Equity Ratio
46.03%
Cash Flow Analysis
Operating Cash Flow Ratio
48.56%
Free Cash Flow Ratio
41.43%
CapEx to Revenue
7.13%
Dividends Paid
$64.85M
Stock Buybacks
No buybacks
Total Shareholder Returns
$64.85M
Cash Position Change
-66.81%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 0.81%
Detailed Growth Metrics
Core Performance
Revenue
2.66%
Net Income
493.81%
EPS
387.50%
Operating Income
-2.30%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
1.86%
Operating Cash Flow
-10.58%
Free Cash Flow
173.30%
Balance Sheet Health
Assets
-9.01%
Debt
-10.83%
Book Value per Share
-6.79%
Inventory
100.00%
Shareholder Returns
Dividends per Share
0.81%
Shares Outstanding
0.13%
Long Term Trends
3Y Revenue/Share
6.10%
5Y Revenue/Share
-11.19%
3Y Dividend/Share
-0.01%
5Y Dividend/Share
-12.30%